Fig. 7From: Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 monthsBoxplot comparing length of treatment between patients who stopped treatment vs patients who continued treatmentBack to article page